Clovis Oncology, Inc. (NasdaqGS:CLVS) is looking for acquisition opportunities. Clovis Oncology commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately to $200 million. The size of offering was upsized from $175 million to $205 million. Clovis Oncology intends to use the net proceeds of the offering for general corporate purposes, including acquisition or licensing of additional product candidates or businesses and working capital.